Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 11;13(10):e18670.
doi: 10.7759/cureus.18670. eCollection 2021 Oct.

Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer

Moayad Alhumaid  1 , Salma Sait  1 , Emad Fallatah  1 , Nasser AlSayegh  1 , Ali Farsi  1 , Mohammed Nassif  1 , Nada J Farsi  2 , Nouf Akeel  1 , Ali Samkari  1 , Alaa A Shabkah  3 , Nora Trabulsi  1
Affiliations
Review

Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer

Moayad Alhumaid et al. Cureus. .

Abstract

Among patients with metastatic colorectal cancer, 25% have isolated peritoneal carcinomatosis. We performed a systematic review and meta-analysis to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing hyperthermic intraperitoneal chemotherapy with oxaliplatin. Eleven studies were included in the final assessment. Pooled three- and five-year OS rates were 58.60% and 42.19%, respectively. The estimated pooled three- and five-year DFS rates were 23.47% and 14.26%, respectively.

Keywords: colorectal neoplasm; cytoreductive surgery (crs); cytoreductive surgery and hipec; oxaliplatin; peritoneal carcinoma; systematic review and meta-analysis.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PRISMA flow diagram of study identification, screening, eligibility, and inclusion.
HIPEC: hyperthermic intraperitoneal chemotherapy; PIPAC: pressurized intraperitoneal aerosol chemotherapy; PRISMA: Preferred reporting items for systematic reviews and meta-analyses.
Figure 2
Figure 2. Overall survival (OS) over time for oxaliplatin-based hyperthermic intraperitoneal chemotherapy. Meta-analysis and forest plots of OS along with summary estimates and 95% confidence intervals (CIs).
The studies are listed in alphabetical order. The horizontal lines represent 95% CI for each study. The squares represent the estimates, with their sizes proportional to the statistical weight of each. The vertical vertex of the diamond illustrates the summary overall survival estimate. The sides of the diamond illustrate 95% CI. ES: effect size Forest plot of two-year OS estimates: Elias et al., 2009 [7], Glockzin et al., 2014 [34], Hompes et al., 2012 [35], Van Leeuwen et al., 2008 [38]. Forest plot of three-year OS estimates: Gervais et al., 2013 [33],  Glockzin et al., 2014 [34], Turrini et al., 2012 [37]. Forest plot of five-year OS estimates: Elias et al., 2009 [7], Faron et al., 2016 [32], Gervais et al., 2013 [33], Quenet et al., 2011 [8], Turrini et al., 2012 [37].
Figure 3
Figure 3. Disease-free survival (DFS) over time for oxaliplatin-based hyperthermic intraperitoneal chemotherapy. Meta-analysis and forest plots of DFS along with summary estimates and 95% confidence intervals (CIs).
The studies are listed in alphabetical order. The horizontal lines represent 95% CI for each study. The squares represent the estimates, with their sizes proportional to the statistical weight of each. The vertical vertexes of the diamonds illustrate the summary disease-free survival estimates. The sides of the diamonds illustrate 95% CI. ES: effect size Forest plot of one-year DFS estimates: Hompes et al., 2012 [35], Turrini et al., 2012 [37]. Forest plot of three-year DFS estimates: Gervais et al., 2013 [33], Turrini et al., 2012 [37]. Forest plot of five-year DFS estimates: Faron et al., 2016 [32], Quenet et al., 2011 [8], Turrini et al., 2012 [37].
Figure 4
Figure 4. Begg’s funnel plot for the assessment of publication bias in 5-year disease-free survival (DFS) and 5-year overall survival (OS) rates.
The horizontal line illustrates the fixed-effects summary estimate, while the sloping lines indicate the expected 95% confidence intervals for a given standard error (SE).
See this image and copyright information in PMC

References

    1. World Health Organization. Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. [ Aug; 2021 ];https://www.who.int/cancer/PRGlobocanFinal.pdf 2018 4:2021.
    1. Peritoneal carcinomatosis from colorectal cancer. Jayne DG, Fook S, Loi C, Seow-Choen F. Br J Surg. 2002;89:1545–1550. - PubMed
    1. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Cancer. 1989;63(2):364–367. - PubMed
    1. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. J Clin Oncol. 2003;21:3737–3743. - PubMed
    1. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Prada-Villaverde A, Esquivel J, Lowy AM, et al. J Surg Oncol. 2014;110:779–785. - PubMed

LinkOut - more resources